".....we were delighted to report positive preclinical data on the ability of PAT-DX3 to be used for synthetic lethality strategies which, along with its potential for the delivery of therapeutic payloads into the cell and cell nucleus, remains an area of high interest with potential partners.”
".....we were delighted to report positive preclinical data on...
-
- There are more pages in this discussion • 101 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.001(14.3%) |
Mkt cap ! $16.46M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.8¢ | 0.7¢ | $2.916K | 398.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 3479285 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1732079 | 8 |
View Market Depth
| Last trade - 16.10pm 20/06/2024 (20 minute delay) ? |
| PAB (ASX) Chart |